NCT01757756

Multiple Dose Safety Toelrability, Pharmacokinetics and Midazolam Interaction In Healthy Overweight And Obese Subjects

A Phase 1 Placebo-Controlled Study To Assess The Safety, Tolerability, Pharmacokinetics And Effect On Midazolam Pharmacokinetics Of Multiple Oral Doses Of PF-05175157 In Otherwise Healthy Overweight And Obese Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This study is designed to assess the safety, tolerability and pharmacokinetics of multiple oral 200-mg doses of Pf-05175157 administered twice daily for 14 days in healthy overweight and obese subjects.

Conditions

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Glucose Metabolism Disorders

Interventions

Type	Name	Description
DRUG	Pf-05175157	200-mg administered twice daily for 14 days
DRUG	placebo	placebo administered twice daily for 14 days
DRUG	midazolam	midazolam 3-mg admistered as single doses on Day 0 and Day 11.

Timeline

• Start date: 2012-10-01
• Primary completion: 2012-11-01
• Completion: 2012-11-01
• First posted: 2012-12-31
• Last updated: 2012-12-31

Locations

1 site across 1 country: United States